Genfit S.A.
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
GNFT | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- PARC EURASANTE, 59120 LOOS
- Website:
- https://www.genfit.fr/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Genfit S.A. is a late-stage biopharmaceutical company dedicated to discovering and developing therapeutic solutions for patients with rare and life-threatening liver diseases with high unmet medical needs. With over two decades of scientific heritage, the company's research and development pipeline targets conditions such as Acute-on-Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE), Cholangiocarcinoma (CCA), and Urea Cycle Disorders (UCD). A key achievement is the development of elafibranor (Iqirvo®), which received marketing authorization in 2024 for the treatment of Primary Biliary Cholangitis (PBC) and is commercialized by a partner. In addition to its therapeutic programs, Genfit operates a diagnostic franchise focused on NASH/MASH and ammonia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Genfit S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Genfit S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Genfit S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
